Zacks.com users have recently been watching Pacific Biosciences (PACB) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies' selection by the University of California, Irvine (UCI) and the GREGoR Consortium (Genomics Research to Elucidate the Genetics of Rare diseases) to support the Pediatric Mendelian Genomics Research Center (MGRC) program to better understand the underlying bi
Pacific Biosciences of California ( NASDAQ:PACB ) First Quarter 2024 Results Key Financial Results Revenue: US$38.8m...